Amortization expense for each of the three-month and six-month periods ended February 28, 2018 and 2017 was $89,375 and $36,875, and $178,750 and $73,750, respectively.
Amortization expense for each of the three-month periods ended February 28, 2018 and 2017 was $1,875, and was $3,750 for each of the six-month periods ended February 28, 2018, and 2017.
Amortization expense for each of the three-month periods ended February 28, 2018 and 2017 was $150,000, and $300,000 for each of the six-month periods ended February 28, 2018 and 2017.
Total amortization expense for intellectual property agreements for the three months and six months ended February 28, 2018 and 2017 was $231,042 and $153,750, respectively, and total amortization expense for the six months ended February 28, 2018 and 2017 was $462,084 and 303,750, respectively.
Amortization of software development costs amounted to $335,723 and $289,659 for the three months ended February 28, 2018 and 2017, respectively, and $621,032 and $573,876 for the six months ended February 28, 2018 and 2017, respectively.
Prior to this lease DILIsym was on a month-to-month rental.
Rent expense, including common area maintenance fees for the three months ended February 28, 2018, and 2017 was $142,459 and $124,604, respectively, and $279,488 and $247,552 for the six months ended February 28, 2018 and 2017, respectively.
On June 1, 2017, as part of the acquisition of DILIsym Services, Inc. the Company acquired certain developed technologies associated with the drug induced liver disease (DILI).The effective rate for the quarter was a benefit of 45.7% compared to an expense of 33.0% in the prior year.
Federal statutory tax rates decreased from 34% to 21% as of January 1, 2018.
In 2QFY17 we incurred approximately $758,000 of research and development costs, of this amount, $349,000 was capitalized and $409,000 was expensed.
Training-related expenses were down $43,000 compared to the prior year.
Training related expenses were down $75,000 compared to the prior year.
Included in the increase was $141,000 of salary expense at DILIsym.
Included in the increase was $280,000 of salary expenses at DILIsym.
In 6moFY17 we incurred approximately $1,283,000 of research and development costs, of this amount, $584,000 was capitalized and $699,000 was expensed.
Overall gross margin as a percentage of revenue decreased by 0.7% to 73.3% in 6moFY18 from 74.0% in 6moFY17.
Overall gross margin as a percentage of revenue decreased by 1.6% to 71.2% in 2QFY18 from 72.8% in 2QFY17.